TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05709340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: proprioceptive neuromuscular facilitation exercises
Description: PNF exercises will be done for Masseter, Temporalis, Lateral pterygoid and medial pterygoid muscles. Each contraction will be held for 10 seconds, and each stretch (relaxation phase) will be allowed to continue as long as the muscle tension continued to give away.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional physical therapy treatment
Description: * Ultrasound: Continuous ultrasound at 1MHZ to temporomandibular joint at 1.0-1.25 W/CM2 for 5 min over each affected TMJ and masseter area, with the mouth in a slightly open position.~* Forward head posture correction exercises including: chin tuck exercise, Strengthening shoulder retractors, stretching of sternocleidomastoid muscle, and Stretching of pectoralis muscle.
Study: NCT06145477

Intervention type: BEHAVIORAL
Intervention: Chicago Parent Program - individualized for families (CPPi)
Description: CPPi is a 8-12 session individual- based parenting skills program
Study: NCT06079619

Intervention type: OTHER
Intervention: Analysis of photos of pigmented tumours by the three groups
Description: Analysis of photos of pigmented tumours by the three groups with different techniques for each group to compare them.

Intervention type: OTHER
Intervention: Analysis of photos of pigmented tumours by the three groups
Description: Analysis of photos of pigmented tumours by the three groups with different techniques for each group to compare them.

Intervention type: OTHER
Intervention: Analysis of photos of pigmented tumours by the three groups
Description: Analysis of photos of pigmented tumours by the three groups with different techniques for each group to compare them.
Study: NCT05651152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JZP441
Description: Nighttime oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nighttime oral dose
Study: NCT06191822

Intervention type: OTHER
Group type: OTHER
Intervention: Nutrition
Description: Interact with mobile app and work toward personalized nutrition goals

Intervention type: OTHER
Group type: OTHER
Intervention: Fitness
Description: Interact with mobile app and work toward personalized fitness goals

Intervention type: OTHER
Group type: OTHER
Intervention: Sleep
Description: Interact with mobile app and work toward personalized sleep goals
Study: NCT05452200

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Solicitation for lung cancer screening
Description: 3 levels of solicitation will be cumulated. First : a Simple collective solicitation of all staff via internal media 4 months later : Personalized indirect solicitation of at-risk groups with information posted in identified areas 4 months later : Personalized direct solicitation of at-risk groups

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: added exams to the usual lung cancer screening
Description: * spirometry examination~* Questionnaires~* Blood samples and breath samples to find biomarkers
Study: NCT05444582

Intervention type: DRUG
Group type: OTHER
Intervention: Levonorgestrel 52 MG Intrauterine System
Description: Eligible participants must be 16-35 years old, meet clinic eligibility for IUD placement, and having a LNG 52 mg IUD placed for either:~Emergency Contraception (had unprotected intercourse in the last 5 days) OR Same-day start - \>7 days since the onset of last menstrual period and have no report of unprotected intercourse in the last 5 days.
Study: NCT05894395

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR booster vaccination (as M-M-R-VaxPro)
Description: a single dose of MMR-containing vaccine (as M-M-R-VaxPro), in adults having previously received 2 lifetime doses of MMR-containing vaccine
Study: NCT05190874

Intervention type: DEVICE
Intervention: Grappler Interference Screw System
Description: Foot and/or ankle procedure involving soft tissue attachment to bone using the Grappler® Interference Screw System
Study: NCT06253377

Intervention type: DEVICE
Intervention: Adsorption membrane filter Oxiris™
Description: Continuous Renal Replacement Therapy with the adsorption membrane filter Oxiris™
Study: NCT05537168

Intervention type: PROCEDURE
Intervention: Pediatric cardiac surgery under cardiopulmonary bypass
Description: All patients with pediatric cardiac surgery under cardiopulmonary bypass between 2008 and 2018 operated at our institution
Study: NCT05776043

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 10 MG
Description: once daily for 6 or 9 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10 MG
Description: once daily for 6 or 9 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily for 3 months
Study: NCT04128761

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scarcity Narrative
Description: Participants are presented with a hypothetical scarcity narrative and asked to listen and consider the scenario.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Neutral Narrative
Description: Participants are presented with a hypothetical neutral narrative and asked to listen and consider the scenario.
Study: NCT03856515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement
Description: Received NRT (Electronic Cigarette - With Nicotine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement
Description: Received NRT (Electronic Cigarette - With Nicotine)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic Cigarette
Description: Electronic Cigarette - with Nicotine

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic Cigarette
Description: Electronic Cigarette - with Nicotine

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic Cigarette
Description: Electronic Cigarette -without Nicotine

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic Cigarette
Description: Electronic Cigarette -without Nicotine
Study: NCT06378996

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 14-day rhythm monitoring
Description: Eligible patients will be monitored during 14 days using the Byteflies patch ambulatory rhythm monitor.
Study: NCT06609603

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HTGT compound
Description: oral administration of HTGT compound once daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of placebo once daily
Study: NCT06000345

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AOT + MI
Description: During the AOT session, the patients were shown a video containing motor contents. In particular, the video demonstrated quadriceps concentric and isometric contractions, presented in the third person perspective. At the conclusion of each video, the patients were asked to spend 1 minute imagining what they had just seen.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control AOT + MI
Description: The control group was shown a video of landscapes (4 minutes in length). Halfway through and at the end of the video they were asked to imagine what they had just seen for 1 minute.
Study: NCT04837651

Intervention type: DEVICE
Intervention: Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test
Description: Subjects will receive an Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test within 4 weeks of receiving their first COVID-19 injection. Within 3-4 weeks of receipt of their final COVID-19 vaccine dose, subjects will receive another Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test.

Intervention type: DEVICE
Intervention: Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test
Description: Subjects will receive an Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test within 4 weeks of receiving their first COVID-19 injection. Within 3-4 weeks of receipt of their final COVID-19 vaccine dose, subjects will receive another Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test.

Intervention type: DEVICE
Intervention: T-Detect COVID T-cell blood test
Description: A select number of subjects will also receive a qualitative SARS-CoV-2 t-cell immunity test, the T-Detect COVID test, within 3-4 weeks of receipt of their final COVID-19 vaccine dose.

Intervention type: DEVICE
Intervention: T-Detect COVID T-cell blood test
Description: A select number of subjects will also receive a qualitative SARS-CoV-2 t-cell immunity test, the T-Detect COVID test, within 3-4 weeks of receipt of their final COVID-19 vaccine dose.
Study: NCT04907565

Intervention type: BIOLOGICAL
Intervention: Blood sampling
Description: 4 tubes of 7 mL of blood will be collected

Intervention type: BIOLOGICAL
Intervention: Blood sampling
Description: 4 tubes of 7 mL of blood will be collected

Intervention type: BIOLOGICAL
Intervention: white adipose tissue sampling
Description: At the beginning of the surgery, samples of white adipose tissue from the surgical wound will be collected.

Intervention type: BIOLOGICAL
Intervention: white adipose tissue sampling
Description: At the beginning of the surgery, samples of white adipose tissue from the surgical wound will be collected.
Study: NCT06095271

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: serum Neurofilament Filament Light chain (sNfL) monitoring
Description: the intervention consist of a blood draw and providing the sNfL information to the treating physician
Study: NCT05101018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Romosozumab (Amgen Inc., Thousand Oaks, CA) 210mg SQ administered each month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: Denosumab (Amgen Inc., Thousand Oaks, CA) 60 mg SQ administered every six months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab (Amgen Inc., Thousand Oaks, CA) 60 mg SQ administered every six months
Study: NCT05022901

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS)
Description: Melphalan administered directly to the liver via the Hepatic Delivery System (HDS) infused over a 30 minute period, followed by a 30 minute washout period
Study: NCT05594381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Neoadjuvant treatment method: Sintilimab 200 mg, i.v., d1 + oxaliplatin 130 mg/m2, d1, i.v., + Tegafur 40 mg po, bid, d1-14; 3-week course; Neoadjuvant therapy: 3 courses of preoperative SOX chemotherapy (oxaliplatin+Tegafur) + PD-1 monoclonal antibody (Sintilimab).~After the 2nd and 3rd cycles of neoadjuvant therapy (6-9 weeks from the start of treatment), imaging effects and feasibility of radical surgery were performed respectively; The operation time is arranged within 2-6 weeks after the last administration of neoadjuvant therapy, and the operation method is selected by the surgeon according to the actual needs; The postoperative treatment plan is the same as the preoperative neoadjuvant treatment plan, and the SOX+Sintilimab will continue to be given until the full 8 cycles (including the preoperative 3 cycles).
Study: NCT05330598

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connected Catheter
Description: The Connected Catheter System is a replaceable wireless urinary prosthesis that is indicated for bladder emptying in male patients who have impaired bladder emptying due to chronic Urinary Retention. The Connected Catheter resides fully internally in the male lower urinary tract (urethra and bladder neck) and remains in place for up to 7 days before removal.
Study: NCT06364787

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: γδ T cells
Description: Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδ T cells from donors will be adoptively transfused.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Targeted drugs
Description: Multi-target kinase inhibitors can act on VEGFR-1,VEGFR-2,VEGFR-3,FGFR1,PDGFR,cKit,Ret and other targets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeted drugs
Description: Multi-target kinase inhibitors can act on VEGFR-1,VEGFR-2,VEGFR-3,FGFR1,PDGFR,cKit,Ret and other targets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PD-1 monoclonal antibody
Description: Humanized programmed death receptor (PD-1) monoclonal antibody that binds to PD- and prevents binding of PD-1 with programed death ligands 1 (PD-L1) and PD-L2. It can function to activate cytotoxic T lymphocytes and inhibit tumor growth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 monoclonal antibody
Description: Humanized programmed death receptor (PD-1) monoclonal antibody that binds to PD- and prevents binding of PD-1 with programed death ligands 1 (PD-L1) and PD-L2. It can function to activate cytotoxic T lymphocytes and inhibit tumor growth.
Study: NCT06475430

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fecal microbiota transplantation
Description: During the treatment, a colonoscopic colonic catheter will be placed via the anus, with the experimental group receiving FMT solution matched to the patient's microbiota for intra-intestinal administration.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Formulated probiotic supplements
Description: During the treatment, a colonoscopic colonic catheter will be placed via the anus, with the control group receiving a standardized probiotic formula.
Study: NCT06040593

Intervention type: OTHER
Intervention: No drug
Description: This is a non-interventional study and no study drug will be provided.

Intervention type: OTHER
Intervention: No drug
Description: This is a non-interventional study and no study drug will be provided.
Study: NCT05612503

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Traditional physical therapy program
Description: resistance-based diaphragm strengthening exercises, breathing exercises to increase costal or chest breathing, and breathing exercises to relax the breathing muscles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional physical therapy program
Description: resistance-based diaphragm strengthening exercises, breathing exercises to increase costal or chest breathing, and breathing exercises to relax the breathing muscles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality-based exercises
Description: Virtual reality exercise using Nintendo Wii systems. As game interfaces, the Nintendo Wii systems employ haptic sensor-based controllers and a balance board.
Study: NCT06378359

Intervention type: OTHER
Intervention: Screening and decolonization for SA carriers with the 3 drug bundle
Description: nasal mupirocin, chlorhexidine gluconate (CHG) mouth rinse and CHG soap showers x 5 days and non-SA carriers receive 2 CHG pre-op showers

Intervention type: OTHER
Intervention: No screening for SA
Description: All receive the 3 drug bundle, Nasal mupirocin, chlorhexidine gluconate (CHG) mouth rinse, and CHG body wash

Intervention type: OTHER
Intervention: no screening
Description: giving pre-surgical patients the three drug decolonization bundle without screening

Intervention type: OTHER
Intervention: Nasal povidone-iodine on surgery day plus 2 CHG pre-op showers without screening.
Description: Nasal povidone-iodine on surgery day plus 2 CHG pre-op showers without screening.

Intervention type: OTHER
Intervention: Nasal alcohol gel on surgery day plus 2 CHG pre-op showers without screening
Description: Nasal alcohol gel on surgery day plus 2 CHG pre-op showers without screening
Study: NCT06394232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eyecyte-RPE™
Description: Eyecyte-RPE™ is a suspension of hiPSCs (human induced Pluripotent Stem Cells) derived Retinal Pigment Epithelial Cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eyecyte-RPE™
Description: Eyecyte-RPE™ is a suspension of hiPSCs (human induced Pluripotent Stem Cells) derived Retinal Pigment Epithelial Cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eyecyte-RPE™
Description: Eyecyte-RPE™ is a suspension of hiPSCs (human induced Pluripotent Stem Cells) derived Retinal Pigment Epithelial Cells
Study: NCT05109182

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Innersight3D
Description: Innersight3D generates a virtual interactive 3D model of the CT scan.
Study: NCT05557513

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: STANDARD Q COVID-19 Ag Test
Description: Device Name: STANDARD Q COVID-19 Ag Test Manufactured by SD Biosensor, Inc., Korea~Purpose: To detect COVID-19 (Its manufacture specification sensitivity was at 84.97% and specificity 98.4%)
Study: NCT06480695

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Berkeley Life Pro Nitrate Capsules
Description: subjects will take 3 capsules 2x a day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Berkeley Life Pro Nitrate Capsules
Description: subjects will take 3 capsules 2x a day

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Exercise
Description: exercise at an intensity midway between the lactate threshold and VO2peak, from the screening test at an RPE of \~ 15-17

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: High Intensity Exercise
Description: exercise at an intensity midway between the lactate threshold and VO2peak, from the screening test at an RPE of \~ 15-17

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Intensity Exercise
Description: exercise at the RPE at LT associated an \~ RPE of 10-12

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Moderate Intensity Exercise
Description: exercise at the RPE at LT associated an \~ RPE of 10-12
Study: NCT05388929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methocarbamol
Description: Methocarbamol after surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Opioid
Description: Standard opioid after surgery or at discharge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Opioid
Description: Standard opioid after surgery or at discharge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Opioid
Description: Standard opioid after surgery or at discharge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard opioid plus methocarbamol
Description: Standard opioid plus methocarbamol after surgery or at discharge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard opioid plus methocarbamol
Description: Standard opioid plus methocarbamol after surgery or at discharge
Study: NCT05451823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Post auriclar-frontal
Description: Frontal sensors will be applied with lead 1 at the center of the forehead; lead 2, 2.8 cm lateral to lead 1; and lead 3 at the temporal area between the lateral canthus and the hairline.~Post auriclar sensors will be applied to the same side of the face, with lead 1 approximately 2.5 cm medial to the mastoid area, post-auricularly next to the hairline. Lead 2 will be attached at the mastoid area and lead 3 will be attached on the same side at the temporal area between the lateral canthus and the hairline.
Study: NCT05198102

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant novel coronavirus vaccine (CHO cells)
Description: At 12 months after the basic immunization (window period ± 3 months), 1 dose of recombinant novel coronavirus vaccine (CHO cells) is vaccinated.
Study: NCT04891237

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10,000 MG01 + 10,000 T517
Description: Purified and polymerized with glutaraldehyde allergen extract, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and Olea (Olea europaea), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30,000 MG01 + 10,000 T517
Description: Purified and polymerized with glutaraldehyde allergen extract, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and Olea (Olea europaea), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The same solution and presentation as the active treatment, but without active ingredients
Study: NCT05559515

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NDPP-Flex
Description: NDPP + patient-centered goal setting

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NDPP
Description: Usual care NDPP only
Study: NCT04630847

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant
Description: FMT utilizing stool from first degree relatives
Study: NCT04921787

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Intensity
Description: Training and education only, a low-intensity strategy inclusive of an HBOT manual, one-time live training on how to use the HBOT manual, and 7 video conference presentations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity
Description: Practice facilitation, a high-intensity strategy inclusive of low-intensity training, plus practice facilitation that is based in part on a program planning model. This study is a hybrid implementation effectiveness design, testing an implementation strategy while observing and gathering information on the clinical intervention's impact on relevant outcomes.